In June, the U.S. Food and Drug Administration (the "FDA") announced that by the end of the year, the agency would issue a draft guidance document addressing the contours of lawful and unlawful off-label promotion. The healthcare industry has heralded this announcement as a positive step in a regulatory environment that, many believe, provides unclear direction regarding the provision of truthful information to healthcare providers, leaving industry players vulnerable to FDA regulatory enforcement, criminal prosecution, and civil suits under the False Claims Act ("FCA").
While the FDA’s announcement was welcomed by many after years of uncertainty and after recent events raised new questions about the constitutionality of the ban on off-label promotion, questions remain about the ultimate effect of the FDA’s decision. First, will the agency provide clear statements regarding the scope of lawful and unlawful off-label promotion, or merely restate existing policy? Other agencies, including the Federal Trade Commission ("FTC") and the Securities and Exchange Commission ("SEC") have been criticized for issuing "new" guidance documents that simply restate the same ambiguous advice that prompted the industry to request their issuance. The FDA has not provided any indication of what its draft guidance will say, and in the absence of an accompanying revision to applicable regulations, it is difficult to predict whether the FDA’s guidance will provide clear advice to the pharmaceutical and medical device industries.
Please see full Alert below for more Information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Topics: Draft Guidance, Enforcement, FCA, FDA, FTC, Healthcare, Medical Devices, Off-Label Promotion, Off-Label Use, Pharmaceutical, SEC
Published In: Administrative Agency Updates, Communications & Media Updates, Consumer Protection Updates, Health Updates, Science, Computers & Technology Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Patterson Belknap Webb & Tyler LLP | Attorney Advertising